Introduction Xingmeng Biopharmaceuticals (Suzhou) Co., Ltd. was established in August of 2016 through the merge and relocation of two of its primary entities: Xingmeng Biotechnology (Beijing) Co., Ltd., which was initially a process research and development center, and Shenzhen Longrui Pharmaceutical Co., Ltd., which served as the original pilot production facility. The company is strategically situated in Phase II of the BioBay of the Suzhou Industrial Park, serving as the operational headquarters in China. Xingmeng is dedicated to the R&D and manufacturing of innovative monoclonal antibody drugs and biosimilars, targeting the treatment of malignant tumors, allergic ailments, infectious diseases, and autoimmune disorders. |